DCT

Participant Engagement and Realities in Decentralized Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, May 22, 2023

TORONTO, May 22, 2023 /PRNewswire-PRWeb/ -- Today's clinical trial landscape offers an unprecedented range of decentralized and hybrid options, including home health and community-based options. Digital solutions have been hailed as the path toward more inclusive trials yet many still struggle to recruit representative patient populations, despite clear regulatory guidance. How can the feedback from participants in recent clinical trials help industry refine its decentralized clinical trial (DCT) approach to be even more inclusive and responsive to patient preferences? How can industry work more collaboratively with advocates who possess distinct lines of site into their communities' needs and experiences around trial participation? In this webinar, the featured speakers will explore solutions to maximizing participant engagement in DCTs.

Key Points: 
  • TORONTO, May 22, 2023 /PRNewswire-PRWeb/ -- Today's clinical trial landscape offers an unprecedented range of decentralized and hybrid options, including home health and community-based options.
  • How can the feedback from participants in recent clinical trials help industry refine its decentralized clinical trial (DCT) approach to be even more inclusive and responsive to patient preferences?
  • In this webinar, the featured speakers will explore solutions to maximizing participant engagement in DCTs.
  • Register today and learn how incorporating patient insights and preferences into decentralized clinical trials can improve inclusivity and increase participant engagement.

eClinical Solutions to Discuss Operationalizing Innovation & Automation in Clinical Trials at Leading Industry Conferences Including OCT Europe, SCDM EMEA, Halloran Core West

Retrieved on: 
Thursday, April 20, 2023

eClinical Solutions will also host various demonstrations at these events to highlight how the elluminate® Clinical Data Cloud helps companies scale digital trials with a unified data foundation and self-service capabilities across stakeholders.

Key Points: 
  • eClinical Solutions will also host various demonstrations at these events to highlight how the elluminate® Clinical Data Cloud helps companies scale digital trials with a unified data foundation and self-service capabilities across stakeholders.
  • “Modern approaches like advanced analytics, machine learning and artificial intelligence are going to be imperative as our industry further operationalizes digital clinical trials.
  • The following day, eClinical Solutions will join clinical operations executives at Halloran Consulting Group’s Clinical Operations Retreat for Executives (CORE) West Coast (April 26-28) in Sonoma, CA.
  • Additional international events eClinical Solutions will attend this spring include the Society for Clinical Data Management (SCDM) 2023 EMEA Conference (April 26-28) in Gothenburg, Sweden.

Depression Clinical Trials: How Remote Methods Can Deliver Stronger Evidence, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, April 19, 2023

TORONTO, April 19, 2023 /PRNewswire-PRWeb/ -- The adoption of hybrid decentralized clinical trial models is increasing in many therapeutic areas, and central nervous system (CNS) is topping the list: CNS studies represent roughly 26 percent of all DCTs conducted since 2015, according to GlobalData's Clinical Trial Database.

Key Points: 
  • In this free webinar, learn about delivering stronger evidence in clinical trials for depression.
  • In this webinar, the featured speakers will address best practices and draw from their personal experiences, highlighting both the opportunities and the challenges of conducting depression clinical trials.
  • The convenience, discretion and regularity of reporting associated with remote participation can provide more accurate clinical outcomes while reducing burden on patients.
  • Register now to learn more about delivering stronger evidence in depression clinical trials.

Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023

Retrieved on: 
Tuesday, April 18, 2023

Avance Clinical CEO, Yvonne Lungershausen has been invited to share the Australian and US CRO experience and future projections with a focus on patient centricity and Decentralized Clinical Trials (DCTs) at the Evolution Europe Summit 2023.

Key Points: 
  • Avance Clinical CEO, Yvonne Lungershausen has been invited to share the Australian and US CRO experience and future projections with a focus on patient centricity and Decentralized Clinical Trials (DCTs) at the Evolution Europe Summit 2023.
  • Avance Clinical was recently identified by GlobalData as a global leader in DCT technology.
  • The Evolution Summit is an invitation-only, premium forum bringing leading clinical research executives and innovative solution providers.
  • https://www.avancecro.com/avance-clinical-north-america-operations/
    - For more information about the benefits of running your next study with Avance Clinical contact us: [email protected]

Customer Award Winners Unveiled at Medidata NEXT Conference

Retrieved on: 
Thursday, March 30, 2023

Medidata , a Dassault Systèmes company, honored life sciences industry innovators and two inspirational leaders during its NEXT conference.

Key Points: 
  • Medidata , a Dassault Systèmes company, honored life sciences industry innovators and two inspirational leaders during its NEXT conference.
  • A highly anticipated feature at the event, the Medidata NEXT Awards recognize excellence in collaboration, sustainability, digital innovation, and patient leadership.
  • The ICON Medical Imaging division partnered with Medidata to deliver several successful studies for sponsors, including a large megastudy.
  • Please see the full schedule of Medidata NEXT Global conferences on the Medidata website.

Everest Group Declares 'The Age of Decentralized Clinical Trials Has Begun'

Retrieved on: 
Wednesday, March 29, 2023

DALLAS, March 29, 2023 /PRNewswire-PRWeb/ -- Everest Group today released its latest research report on Decentralized Clinical Trials, which documents a 38% increase from 2021 to 2022 in the number of trials conducted with a decentralized and/or virtual component. Everest Group predicts that the adoption of DCTs by pharmaceutical companies will rapidly accelerate as early adopters praise the approach for putting patient experience at the forefront.

Key Points: 
  • Everest Group also joins DTRA, offering members accessibility to pioneering research on clinical technology
    DALLAS, March 29, 2023 /PRNewswire-PRWeb/ -- Everest Group today released its latest research report on Decentralized Clinical Trials, which documents a 38% increase from 2021 to 2022 in the number of trials conducted with a decentralized and/or virtual component.
  • These findings and more are detailed in the Decentralized Clinical Trials Adoption Playbook .
  • Everest Group also released today its 2023 Life Sciences Decentralized Clinical Trial Platforms State of the Market Report , which analyzes the current state of the DCT market.
  • Everest Group also announced today that it has joined the Decentralized Trials Research Alliance (DTRA) to support the organization's mission of advancing policies, research practices and new technologies to make clinical trial participation widely accessible.

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 22, 2023

Several FDA-approved neoadjuvant therapies exist for ER- breast cancers, but few exist for ER+ patients, which account for approximately 78% of breast cancers.

Key Points: 
  • Several FDA-approved neoadjuvant therapies exist for ER- breast cancers, but few exist for ER+ patients, which account for approximately 78% of breast cancers.
  • We expect to enroll approximately 175 patients at up to 25 sites across the United States.
  • Continued Enrollment in Phase 2 Karisma-Endoxifen Study – The Karisma-Endoxifen study is our randomized, double-blind, placebo-controlled trial of healthy, pre-menopausal women with increased breast density.
  • Our investment totaled $4.7 million and resulted in Atossa owning approximately 19% of the outstanding capital stock of DCT.

Surging Power and Precise Control: GAC MOTOR EMPOW Officially Released in Saudi Arabia

Retrieved on: 
Wednesday, March 15, 2023

GUANGZHOU, China, March 15, 2023 /PRNewswire/ -- On 14 March, GAC MOTOR launched EMPOW, a sporty sedan featuring cutting-edge design and innovations, in Saudi Arabia.

Key Points: 
  • GUANGZHOU, China, March 15, 2023 /PRNewswire/ -- On 14 March, GAC MOTOR launched EMPOW, a sporty sedan featuring cutting-edge design and innovations, in Saudi Arabia.
  • Football star and GAC MOTOR Saudi Arabia brand ambassador Salem Al-Dawsari sent his greetings remotely via video.
  • "Saudi Arabia is one of the most important strategic markets for GAC MOTOR in the Middle East," said Zeng.
  • "We will seize the opportunity of in-depth cooperation between China and Saudi Arabia to fully promote the development of Saudi Arabia's market."

Mural Health and ProofPilot Partner to Streamline Payments and Provide More Patient Choice

Retrieved on: 
Tuesday, March 14, 2023

BERWYN, Pa. and NEW YORK, March 14, 2023 /PRNewswire/ -- Mural Health, a clinical trials technology company that improves the patient and caregiver experience in order to improve enrollment rates, participant retention, and increase protocol compliance and ProofPilot, the industry's first digital protocol automation platform for clinical trial, today announced a strategic partnership to further advance clinical trial operations for life science customers. Through this partnership, Mural Health's Mural Link™ platform and ProofPilot's platform work together to progress clinical operations and materially improve the efficiency, and outcomes, of global clinical trials.

Key Points: 
  • Through this partnership, Mural Health's Mural Link™ platform and ProofPilot 's platform work together to progress clinical operations and materially improve the efficiency, and outcomes, of global clinical trials.
  • Rigorous participant compliance in research is driven by the ability to responsibly incentivize successful and timely completion of specific tasks.
  • "We are excited to partner with ProofPilot, creating a complementary, next generation digital protocol automation ecosystem to deliver a wide variety of integrated functions to our mutual customers."
  • "At ProofPilot, we have always seen a higher degree of patient compliance when payments can be automated and closely tied to a wide variety of tasks.

Mural Health and ProofPilot Partner to Streamline Payments and Provide More Patient Choice

Retrieved on: 
Tuesday, March 14, 2023

BERWYN, Pa. and NEW YORK, March 14, 2023 /PRNewswire/ -- Mural Health, a clinical trials technology company that improves the patient and caregiver experience in order to improve enrollment rates, participant retention, and increase protocol compliance and ProofPilot, the industry's first digital protocol automation platform for clinical trial, today announced a strategic partnership to further advance clinical trial operations for life science customers. Through this partnership, Mural Health's Mural Link™ platform and ProofPilot's platform work together to progress clinical operations and materially improve the efficiency, and outcomes, of global clinical trials.

Key Points: 
  • Through this partnership, Mural Health's Mural Link™ platform and ProofPilot 's platform work together to progress clinical operations and materially improve the efficiency, and outcomes, of global clinical trials.
  • Rigorous participant compliance in research is driven by the ability to responsibly incentivize successful and timely completion of specific tasks.
  • "We are excited to partner with ProofPilot, creating a complementary, next generation digital protocol automation ecosystem to deliver a wide variety of integrated functions to our mutual customers."
  • "At ProofPilot, we have always seen a higher degree of patient compliance when payments can be automated and closely tied to a wide variety of tasks.